Work Here?
Selux Diagnostics
Work Here?
Rapid antibiotic susceptibility testing for hospitals
Selux Diagnostics
Work Here?
Rapid antibiotic susceptibility testing for hospitals
About Selux Diagnostics
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Late Stage VC
Total Funding
$252.4M
Headquarters
Boston, Massachusetts
Founded
2014
Overview
Selux Diagnostics provides rapid, comprehensive antibiotic susceptibility testing (AST) to hospitals and healthcare providers. It helps identify which antibiotics will effectively treat a bacterial infection by testing against all commercially relevant antibiotics at once, enabling faster and more accurate prescription decisions. By delivering quicker results and updating interpretive breakpoints, Selux addresses antimicrobial resistance and preserves antibiotic effectiveness. The company differentiates itself through its ability to run broad-spectrum AST in a single assay, improving turnaround times and coverage compared with traditional AST methods. Its goal is to reduce inappropriate antibiotic use in hospitals, lower AMR risks, and save lives by ensuring patients receive the right antibiotic therapy sooner.
Simplify's Take
What believers are saying
- Same-day AST results reduce broad-spectrum antibiotic overuse and combat antimicrobial resistance epidemic.
- $48M Series funding round in April 2024 accelerates U.S. commercialization and market expansion.
- FDA Breakthrough Device Designation and three 510(k) clearances validate NGP platform's clinical utility.
What critics are saying
- Accelerate Diagnostics' qPCR systems deliver results in under 2 hours versus Selux's 5.5 hours.
- BD and Copan's integrated workflows lock hospitals into competing ecosystems, blocking NGP adoption.
- FDA post-market studies reveal 5–10% categorical errors in NGP versus gold-standard BMD testing.
What makes Selux Diagnostics unique
- Only single-platform technology delivering rapid AST from positive blood cultures and isolated colonies simultaneously.
- Proprietary Viability and Surface Area Assays detect dying cells without waiting for cell death.
- 384-well panel enables comprehensive testing against all commercially relevant antibiotics at once.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$252.4M
Above
Industry Average
Funded Over
12 Rounds
Benefits
Health Insurance
401(k) Company Match
Unlimited Paid Time Off
Parental Leave
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↓ -10%2 year growth
↑ 5%Arlington, Va.-based Sands Capital has joined a $48 million funding round for Selux Diagnostics, a biotech startup promising personalized therapies.
This additional funding comes at the heels of Selux announcing their third FDA 510(k) clearance on their direct from Positive Blood Culture Separator, making them the only single-platform technology capable of delivering rapid AST results for both positive blood culture and isolated colonies.
SeLux Diagnostics has filed a notice of an exempt offering of securities to raise $45,000,000.00 in New Debt Financing. SeLux Diagnostics has filed a notice of an exempt offering of securities to raise $45,000,000.00 in New Debt Financing.According to filings with the U.S. Securities and Exchange Commission, SeLux Diagnostics is raising up to $45,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Steve Lufkin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About SeLux DiagnosticsSelux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic. The CDC has cited bacterial resistance to antibiotics among the worlds deadliest and costliest health threats
SeLux Dx: The company raised $40 million of venture funding in the form of convertible debt from undisclosed investors on February 13, 2024.
Approval gives way to the most comprehensive single menu offered by an AST platform while delivering precise, rapid results in 5.5 hours from isolated colonies. . .
There are no jobs for Selux Diagnostics right now.
Find jobs on Simplify and start your career today
About Selux Diagnostics
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Late Stage VC
Total Funding
$252.4M
Headquarters
Boston, Massachusetts
Founded
2014
There are no jobs for Selux Diagnostics right now.
Find jobs on Simplify and start your career today